Clinical Trial Update: NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial, NeoLIPA, is evaluating neoadjuvant LTX-315 in combination with pembrolizumab for resectable stage III/IV melanoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LTX-315 (LTX-315 peptide)

Snippet

Sponsor: Oslo University Hospital | Conditions: Melanoma Stage IIIB-IV | Phase 2 | Status: RECRUITING